<DOC>
	<DOCNO>NCT02859493</DOCNO>
	<brief_summary>This study aim evaluate effect specific strain Saccharomyces cerevisiae improve effectiveness conventional treatment vulvo-vaginal candidiasis . This randomized , double-blind , placebo-controlled study . The administration yeast local ( vaginal ) .</brief_summary>
	<brief_title>Effect Saccharomyces Cerevisiae Vulvo-vaginal Candidiasis</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Vulvovaginal</mesh_term>
	<criteria>Subject suffer vulvovaginal candidiasis ( accord clinical examination ) characterize vaginal discharge associate follow symptom : itch burn vaginal feeling , dyspareunia dysuria . Amenorrheic subject , subject regular menstrual cycle . Subject psychologically able understand study relate information give write informed consent . Subject give freely expressly informed consent . Subject able comply protocol requirement , define protocol . Subject affiliate health social security system . Female subject childbearing potential use medically accept contraceptive regimen ( except latex condom , latex diaphragm , spermicidal ) D0D14 period , since least 12 week begin study , study least 1 month study end , investigator 's discretion In term population Pregnant nursing woman plan pregnancy study . Postmenopausal woman . Subject period first second visit gynaecologist ( D0 D7 ) . Subject deprive freedom administrative legal decision guardianship . Subject social sanitary establishment . Subject suspect noncompliant accord investigator 's judgment . Subject enrol another clinical trial test zone within four previous week study period , exclusion period previous study , test food supplement medication 4 previous week . Subject emergency situation . In term associated pathology Subject condition receive medication , investigator 's judgment , put subject undue risk . Subject suffer systemic disease use concurrent therapy may interfere evaluation study result . Subject know allergy one component study product medication ( vaginal ovule and/or antifungal cream ) . Subject present hypersensitivity antifungal imidazole family one excipient . Uterine vaginal bleed unknown origin Subject know sexually transmitted infection Neisseria gonorrhoea , Chlamydia trachomatis , Treponema pallidum , herpes simplex , Trichomonas vaginalis , human papilloma virus HIV 1 2 . Immunocompromised subject Relating previous ongoing treatment â€¢ Subject undergoing topical treatment test area systemic intravaginal treatment : antibiotic currently within past 2 week ( systemic antibiotic accept treatment stop day inclusion visit ) antifungal agent currently within past 2 week , anticoagulant within past 2 week study , antiinflammatory medication and/or antihistamines previous 2 week study , corticosteroid 2 previous week study , retinoids and/or immunosuppressor 3 previous month study , medication stabilize less one month . In term lifestyle Subject planning change usual hygiene habit product study . Subjects willing stop take probiotic dietary supplement food product enrich probiotic .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>